Clinical trials
catalyst calendar across sponsors →Studies where BBNX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 observational
Held by 7 tracked-famous managers (Point72 Asset Management, L.P., MILLENNIUM MANAGEMENT LLC, Balyasny Asset Management L.P., AQR CAPITAL MANAGEMENT LLC, Squarepoint Ops LLC, +2 more) · FINRA short interest 6.0 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 12 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| The iLet Experience StudyNCT06891898observationalSevere Hypoglycemia/cognitive impairment | — | Recruiting | Device: iLet Dosing Decision Software | Type 1 Diabetes | 1,875 | Jun 2027 | ≤ 314 d | 2025-03-24 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19